$200K in sales so far for the year. That’s probably about 10-12 devices. Not a lot but probably all in NZ. So, it’s an encouraging sign if sales can eventually be made in the UK and the rest of Europe.
What was also interesting to read is that they look like partnering up with distributors in the EMEA region. So, if it happens and distribution channels are established this will be positive for eventual sales.
Another good sign is that they are thinking of plans to obtain public reimbursement funding from hospitals directly in Germany and maybe elsewhere.
They look at least closer to finalising data package for the FDA for bile duct. So, that’s at least encouraging.
New Chairman will also be a positive with a renewed Board.
So, next 6-12 months will be more interesting than the last year.
OSL Price at posting:
5.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)